You'll see even more prescriptions for Evista

You'll see even more prescriptions for Evista.

The FDA just approved it for postmenopausal women with osteoporosis...or postmenopausal women at high risk for breast cancer.

Many prescribers already use Evista (raloxifene) as an alternative to tamoxifen to reduce breast cancer risk.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 120+ CE courses, including the popular CE-in-the-Letter
  • Helpful, in-depth Technician Tutorials
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote